Multiple agents that target VEGF signalling have been explored as monotherapy in melanoma, including bevacizumab, aflibercept, axitinib, vatalanib, sunitinib, dovitinib, and sorafenib; however, only a few demonstrated modest clinical activity (Nikolaou et al, 2012). The gene discussed is VEGFA; the disease is melanoma.